SCHEMBL6325105

SCHEMBL6325105

COc1ccc(-c2nc(CCC(=O)O)no2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 4/20 0.51
FFAR1 O14842 1/20 0.48
LMNA P02545 1/20 0.44
ATM Q13315 1/20 0.44
OXTR P30559 1/20 0.44
FFAR4 Q5NUL3 1/20 0.42
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MITF O75030 1/20 0.40
TP53 P04637 1/20 0.40
NCOA3 Q9Y6Q9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6326082 0.89 SMPD1 (0.41) S1PR1OXTRMKNK1MKNK2KDM4E
SCHEMBL6326248 0.78 LMNA (0.70) FFAR1LMNAATMALDH1A1MAPT
SCHEMBL15058774 0.76 FFAR1 (0.66) FFAR1LMNAKDM4ENPC1ALDH1A1
SCHEMBL1840673 0.75 MKNK1 (0.56) FFAR1LMNAFFAR4MKNK1MKNK2
SCHEMBL22630224 0.73 GABRA5 (0.48) LMNAOXTRKDM4EALDH1A1MAPT
SCHEMBL22628961 0.73 GABRA5 (0.55) S1PR1LMNAMKNK1MKNK2NPC1
SCHEMBL29886594 0.71 P4HTM (0.58) FFAR1LMNAFFAR4NPC1PKM
SCHEMBL6069860 0.71 P4HTM (0.58) FFAR1LMNAFFAR4NPC1PKM
SCHEMBL15058475 0.70 SMN1; SMN2 (0.57) S1PR1FFAR1LMNAKDM4ENPC1
SCHEMBL31689010 0.70 FFAR1 (0.56) FFAR1LMNAFFAR4MKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 EP disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 US disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 S1PR1 1224/4885FFAR1 2536/4885LMNA 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.